| P2093 | author name string | William Stohl | |
| | David M Hilbert | |
| P2860 | cites work | BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth | Q22009942 |
| | TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease | Q22254041 |
| | TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation | Q22254448 |
| | Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS | Q24290135 |
| | Impaired IgA class switching in APRIL-deficient mice | Q24313032 |
| | BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2 | Q27639845 |
| | BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator | Q28139180 |
| | Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity | Q28139967 |
| | Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI | Q28140973 |
| | Characterization of a new member of the TNF family expressed on antigen presenting cells | Q28144198 |
| | TALL-1 is a novel member of the TNF family that is down-regulated by mitogens | Q28144231 |
| | Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase | Q28144774 |
| | APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity | Q28145384 |
| | Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator | Q28183674 |
| | Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency | Q28190857 |
| | BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases | Q28205999 |
| | BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF | Q28213294 |
| | A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus | Q28254310 |
| | APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells | Q28263864 |
| | Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence | Q28289843 |
| | A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys | Q28293722 |
| | The biology of CD20 and its potential as a target for mAb therapy | Q28295215 |
| | Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial | Q28304807 |
| | APRIL-deficient mice have normal immune system development | Q28511017 |
| | B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells | Q28590517 |
| | Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project | Q33383576 |
| | B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data | Q33542751 |
| | Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus | Q33928629 |
| | Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. | Q33951524 |
| | Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF | Q33960050 |
| | BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis | Q34012753 |
| | Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. | Q34144779 |
| | B cells regulate autoimmunity by provision of IL-10. | Q34150590 |
| | Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis | Q34327451 |
| | Similarities and differences between selective and nonselective BAFF blockade in murine SLE | Q34350295 |
| | B Cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice | Q34781487 |
| | Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus | Q34802966 |
| | Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression | Q34831296 |
| | B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels | Q34895937 |
| | Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway | Q34939962 |
| | Cellular competition independent of BAFF/B lymphocyte stimulator results in low frequency of an autoreactive clonotype in mature polyclonal B cell compartments | Q35058903 |
| | Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice | Q35110335 |
| | Regulation of the B cell receptor repertoire and self-reactivity by BAFF | Q35686885 |
| | BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population | Q35834649 |
| | Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial | Q35993027 |
| | Chemokines and their receptors in rheumatoid arthritis: future targets? | Q36063483 |
| | The role of B cells in lpr/lpr-induced autoimmunity | Q36363909 |
| | A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth | Q36368318 |
| | Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response | Q36368953 |
| | Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations | Q36375661 |
| | High serum levels of BAFF, APRIL, and TACI in common variable immunodeficiency | Q36800138 |
| | Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus | Q36993242 |
| | Protective and pathogenic roles for B cells during systemic autoimmunity in NZB/W F1 mice | Q37072796 |
| | Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity | Q37072801 |
| | Novel evidence-based systemic lupus erythematosus responder index | Q37356378 |
| | A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus | Q37378350 |
| | The role of IL-23/IL-17 axis in lupus nephritis | Q37397437 |
| | BAFF mediates survival of peripheral immature B lymphocytes | Q42944182 |
| | T cell costimulation by the TNF ligand BAFF. | Q43803679 |
| | An open study of B lymphocyte depletion in systemic lupus erythematosus | Q44183280 |
| | Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. | Q44223059 |
| | Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial | Q46353641 |
| | BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. | Q46726060 |
| | Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. | Q47365613 |
| | BAFF augments certain Th1-associated inflammatory responses. | Q47810975 |
| | Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. | Q51966554 |
| | Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus. | Q54574124 |
| | Rituximab and lupus: Good in real life, bad in controlled trials. comment on the article by Lu et al | Q56907482 |
| | An Essential Role for BAFF in the Normal Development of B Cells Through a BCMA-Independent Pathway | Q57230082 |
| | TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice | Q74108088 |
| | TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS | Q74419758 |
| | B lymphocytes from individuals with common variable immunodeficiency respond to B lymphocyte stimulator (BLyS protein) in vitro | Q79247263 |
| | B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time | Q79324671 |
| | B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab | Q80502406 |
| | Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept | Q81394138 |
| | Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects | Q82732869 |
| P433 | issue | 1 | |
| P921 | main subject | belimumab | Q1996249 |
| P304 | page(s) | 69-77 | |
| P577 | publication date | 2012-01-09 | |
| P1433 | published in | Nature Biotechnology | Q1893837 |
| P1476 | title | The discovery and development of belimumab: the anti-BLyS-lupus connection | |
| P478 | volume | 30 | |